759 results
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
25 Apr 24
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
7:47am
above, the decrease was also due to lower litigation and other settlement income. The company reported on a non-GAAP basis net loss attributable … such transactions and actions; the risk of an adverse patent litigation decision or settlement and exposure to other litigation and/or regulatory actions
8-K
EX-99.2
BMY
Bristol-Myers Squibb Co.
25 Apr 24
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
7:47am
under the Private Securities Litigation Reform Act of 1995. All statements that are not statements of historical facts are, or may be deemed
DEFA14A
BMY
Bristol-Myers Squibb Co.
22 Apr 24
Additional proxy soliciting materials
8:16am
and address rising litigation and insurance costs for shareholders. As is currently the case with directors under our Certificate of Incorporation … under the Private Securities Litigation Reform Act of 1995. All statements that are not statements of historical facts are, or may be deemed
8-K
EX-4.1
yvq0t6
22 Feb 24
Other Events
4:15pm
424B5
fea v6bg7wh
16 Feb 24
Prospectus supplement for primary offering
4:34pm
424B2
klidt 2lhema
13 Feb 24
Prospectus for primary offering
8:00am
SC TO-T/A
z2votklk
12 Feb 24
Third party tender offer statement (amended)
7:34am
8-K
EX-99.2
42owi72q2d7wp
2 Feb 24
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
7:46am